Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin®, Genzyme), Tacrolimus (Prograf®, Astellas), Mycophenolate Mofetil (CellCept®, Roche) and Corticosteroid Minimization

The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and corticosteroid therapy.

Study Overview

• Status: Completed
• Conditions: Kidney Transplantation
• Intervention / Treatment: Drug: Rabbit Antithymocyte Globulin; Drug: Rituxan; Drug: Velcade

Detailed Description

Optimal induction regimens for patients at high risk for antibody and/or cell-mediated rejection have not been established. This pilot, prospective, randomized study evaluated addition of B cell/plasma cell-targeting agents to T cell-based induction with rabbit antithymocyte globulin (rATG) in high immunologic risk renal transplant recipients. Patients were randomized to induction with rATG, rATGþrituximab, rATGþbortezomib or rATGþrituximabþbortezomib.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • The University Hospital
    • Cincinnati, Ohio, United States, 45202
      • The Christ Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
• Patient is between the 18 and 65 years of age, inclusive.

• Patient is considered high risk for acute rejection based on any one of the following:

  • Patient has a current Cytotoxic PRA≥ 20% or a peak Cytotoxic PRA ≥50%
  • Patient has a T or B-cell positive crossmatch (by flow cytometry) with confirmed donor-specific antibodies on solid-phase assay.
  • Historical positive serologic or cytotoxic crossmatch or DSA to donor
  • Prior allograft loss with a history of more than one acute rejection episode.
• Female subject is either postmenopausal for at least 1 year prior to initiation of study treatment, is surgically sterilized, or if of childbearing potential, agrees to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agrees to completely abstain from heterosexual intercourse. Women of childbearing potential must have a negative serum pregnancy test within the last 48 hours prior to receiving study medication.
• Male subjects, even if surgically sterilized (i.e. status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.
• Patient must have no known contraindications to treatment with bortezomib, rituximab, or thymoglobulin.

Exclusion Criteria

• Patients that have previously received or are receiving an organ transplant other than kidney.
• Patient who lost a previous allograft due to recurrence of disease
• Patient is receiving a HLA identical living related kidney transplant
• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal or polyclonal antibodies
• Patients with an absolute neutrophil count of < 1,000/mm3 or platelet count < 100,000/mm3within 30 days of consent.
• Patient has Grade 2 peripheral neuropathy by CTCAE criteria within 14 days before enrollment.
• Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 9.3), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality on ECG performed within 30 days of consent has to be documented by the investigator or the patient's transplant nephrologist as not medically relevant.
• Patients who are anti-HIV-positive, or HBsAg-positive or Anti-HCV positive on testing performed within one year of consent.
• Diagnosed or treated for malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
• Patients with current or recent severe systemic infections within the 2 weeks prior to initiation of study treatment.
• Receipt of a live vaccine within 4 weeks prior to initiation of study treatment.
• Use of other investigational drugs within 30 days or 5 half-lives prior to initiation of study treatment, whichever is longer
• Evidence of severe liver disease by medical history or physical exam with abnormal liver profile (aspartate aminotransferase [AST], alanine aminotransferase [ALT] or total bilirubin > 1.5 times upper limit of normal [ULN]) on testing performed within 30 days of consent.
• Pregnant or nursing (lactating) women and women who might become pregnant during the study. Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum -human chorionic gonadotropin pregnancy test result within the last 48 hours prior to receiving study medication. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
• EBV serologic mismatch (i.e. EBV+ donor transplanted to EBV- recipient)
• CMV serologic mismatch (i.e. CMV+ donor transplanted to CMV- recipient)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Rabbit Antithymocyte Globulin (rATG); Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.	Drug: Rabbit Antithymocyte Globulin; rATG will be given 1.5mg/kg intravenous (IV) per dose.; Other Names: Thymoglobulin; rATG
Experimental: RATG/Rituxan; Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.	Drug: Rabbit Antithymocyte Globulin; rATG will be given 1.5mg/kg intravenous (IV) per dose.; Other Names: Thymoglobulin; rATG; Drug: Rituxan; Given via IV per group assignment.; Other Names: Rituximab
Experimental: RATG/Velcade; Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.	Drug: Rabbit Antithymocyte Globulin; rATG will be given 1.5mg/kg intravenous (IV) per dose.; Other Names: Thymoglobulin; rATG; Drug: Velcade; Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.; Other Names: bortezomib
Experimental: RATG/Rituxan/Velcade; Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1.	Drug: Rabbit Antithymocyte Globulin; rATG will be given 1.5mg/kg intravenous (IV) per dose.; Other Names: Thymoglobulin; rATG; Drug: Rituxan; Given via IV per group assignment.; Other Names: Rituximab; Drug: Velcade; Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.; Other Names: bortezomib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Acute Rejection (Banff '97) or Antibody Mediated Rejection	Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria. Acute rejection IA - cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells). IB - cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of severe tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising >25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antibody-mediated Rejection by Banff '97 Criteria (Updated 2005)	Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria. Rejection due, at least in part, to documented anti-donor antibody ('suspicious for' if antibody not demonstrated); may coincide with categories 3, 4 and 5. Grade I. ATN-like - C4d+, minimal inflammation Grade II. Capillary- margination and/or thromboses, C4d+ Grade III. Arterial - v3, C4d+	6 months
Acute Cellular Rejection by Banff '97 Criteria (Updated 2005)	Acute cellular rejection IA - cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells). IB - cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of severe tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising >25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)	6 months
Patient Survival at 12 Months	Patient was still alive 12 months post study enrollment.	12 months
Patient Allograft Survival at 12 Months	Patient's allograft was still functioning at 12 months post study enrollment	12 months

Collaborators and Investigators

• Sponsor: University of Cincinnati
• Collaborators: Genzyme, a Sanofi Company; Millennium Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start: September 1, 2008
• Primary Completion (Actual): February 1, 2013
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: October 29, 2008
• First Submitted That Met QC Criteria: October 29, 2008
• First Posted (Estimate): October 31, 2008

Study Record Updates

• Last Update Posted (Estimate): January 20, 2016
• Last Update Submitted That Met QC Criteria: December 14, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Keywords: Rejection; Immunology; Transplantation; Kidney; Renal; Allograft; B Cell; Desensitization; Induction; High risk
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab; Bortezomib; Thymoglobulin; Antilymphocyte Serum
• Other Study ID Numbers: X05274